Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001363942 | SCV001560074 | uncertain significance | Brugada syndrome | 2020-04-27 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SCN10A-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces threonine with arginine at codon 34 of the SCN10A protein (p.Thr34Arg). The threonine residue is weakly conserved and there is a moderate physicochemical difference between threonine and arginine. |
Mayo Clinic Laboratories, |
RCV002261355 | SCV002542046 | uncertain significance | not provided | 2022-02-04 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004036895 | SCV005024919 | uncertain significance | Cardiovascular phenotype | 2024-07-26 | criteria provided, single submitter | clinical testing | The c.101C>G (p.T34R) alteration is located in exon 1 (coding exon 1) of the SCN10A gene. This alteration results from a C to G substitution at nucleotide position 101, causing the threonine (T) at amino acid position 34 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |